A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

Inclusion Criteria: * Signed informed consent * Age \>=50 years * Active primary or recurrent subfoveal CNV lesions secondary to AMD in the study eye * Total area of CNV (including both classic and occult components) encompassed within the lesion \>= 50% of the total lesion area * Total lesion area \<=12 disc areas in size * Best corrected visual acuity (BCVA), using Early Treatment of Diabetic Retinopathy Study (ETDRS) charts, of 20/40 to 20/320 (Snellen equivalent) in the study eye Exclusion Criteria: * Prior treatment with verteporfin, external-beam radiation therapy, or transpupillary thermotherapy in the study eye * Treatment with verteporfin in the nonstudy eye \<7 days preceding Day 0 * Previous participation in a clinical trial (for either eye) involving anti-angiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase C inhibitors, etc.) * Previous intravitreal drug delivery (e.g., intravitreal corticosteroid injection or device implantation) in the study eye * Previous subfoveal focal laser photocoagulation in the study eye * Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month preceding Day 0 * History of vitrectomy surgery in the study eye * History of submacular surgery or other surgical intervention for AMD in the study eye * Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals) * Subretinal hemorrhage in the study eye that involves the ce…